Compare FIBK & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIBK | TLX |
|---|---|---|
| Founded | 1879 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | 2010 | N/A |
| Metric | FIBK | TLX |
|---|---|---|
| Price | $34.76 | $7.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $36.00 | $21.00 |
| AVG Volume (30 Days) | ★ 1.1M | 203.3K |
| Earning Date | 01-28-2026 | 01-15-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 3.95 | N/A |
| EPS | ★ 2.37 | 0.04 |
| Revenue | ★ $953,700,000.00 | $664,225,558.00 |
| Revenue This Year | $9.24 | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | ★ $14.60 | $233.34 |
| Revenue Growth | 0.26 | ★ 55.35 |
| 52 Week Low | $22.95 | $7.49 |
| 52 Week High | $36.35 | $30.36 |
| Indicator | FIBK | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 28.22 |
| Support Level | $35.28 | $7.72 |
| Resistance Level | $36.03 | $8.22 |
| Average True Range (ATR) | 0.54 | 0.22 |
| MACD | -0.17 | -0.06 |
| Stochastic Oscillator | 1.19 | 0.78 |
First Interstate BancSystem Inc is a financial holding company. It is the parent company of First Interstate Bank, a community bank offering a range of internet, mobile, and other banking and financial services throughout Idaho, Montana, Oregon, South Dakota, Washington, and Wyoming. It delivers a range of financial products and services to both retail and commercial customers in industries like agriculture, construction, education, energy, governmental services, healthcare, mining, professional services, retail, tourism and wholesale trade. It generates majority of income from interest charged on loans, and interest and dividends earned on investments.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.